^
    over2years
    A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors. (PubMed, Adv Sci (Weinh))
    In vivo, WBC100 potently regresses multiple lethal c-Myc overexpressing tumors such as acute myeloid leukemia, pancreatic, and gastric cancers with good tolerability in multiple xenograft mouse models. Identification of the NLS1-Basic-NLS2 region as a druggable pocket for targeting the "undruggable" c-Myc protein and that single-agent WBC100 potently regresses c-Myc overexpressing tumors through selective c-Myc proteolysis opens new perspectives for pharmacologically intervening c-Myc in human cancers.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC overexpression • MYC expression
    |
    WB100
    almost3years
    Clinical Trial of WB100 on Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=60, Recruiting, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CA 19-9 (Cancer antigen 19-9)
    |
    MYC overexpression • MYC expression • MYC positive
    |
    WB100
    3years
    Clinical Trial of WB100 on Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Zhejiang University
    Clinical • New P1 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CA 19-9 (Cancer antigen 19-9)
    |
    MYC overexpression • MYC expression • MYC positive
    |
    WB100